- Ongoing, recruitingTherapeutic exploratory (Phase II)
Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated with Amivantamab, an EGFR-MET bispecific antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study
This study looks at ways to prevent infusion reactions in people with advanced lung cancer receiving a new combination of medicines. Researchers are testing different medications given before treatment to see if they can reduce side effects when the main cancer drug is given through a drip.
For: EGFR-mutated Advanced or Metastatic Non-small Cell Lung CancerFrance · Spain - AuthorisedTherapeutic exploratory (Phase II)
Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations
This study looks at a new treatment called amivantamab with chemotherapy for people with a specific type of lung cancer (NSCLC) where standard treatments haven't worked well. It aims to see how many people respond to the treatment.
For: Non-small cell lung cancer (NSCLC)Italy